Filing Details

Accession Number:
0000899243-23-007602
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-08 18:47:06
Reporting Period:
2023-03-06
Accepted Time:
2023-03-08 18:47:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1521036 Lantheus Holdings Inc. LNTH In Vitro & In Vivo Diagnostic Substances (2835) 352318913
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1801395 Paul Blanchfield C/O Lantheus Holdings, Inc.
201 Burlington Road, South Building
Bedford MA 01730
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-06 5,250 $72.56 89,101 No 4 S Direct
Common Stock Disposition 2023-03-07 2,758 $72.15 86,343 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transactions reported in this Form 4 were effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.